Brequinar
Small moleculeexperimental
Brequinar (DuP-785) is a drug that acts as a potent and selective inhibitor of the enzyme dihydroorotate dehydrogenase. It blocks synthesis of pyrimidine based nucleotides in the body and so inhibits cell growth. Brequinar was invented by DuPont Pharmaceuticals in the 1980s. In 2001, Bristol-Myers Squibb acquired DuPont, and in 2017, Clear Creek Bio acquired the rights to brequinar from BMS. — Wikipedia
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Nov 26, 2018 (NCT03760666)
Timeline
Indications
Mechanism of action
- Dihydroorotate dehydrogenaseINHIBITOR
DHODH inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1c(-c2ccc(-c3ccccc3F)cc2)nc2ccc(F)cc2c1C(=O)[O-].[Na+]- Mol. weight
- 397.36 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBrequinar ↗
- ChEMBLCHEMBL38434 ↗
- ChEMBLCHEMBL300058 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05166876 | Phase 2 | Feb 1, 2022 | Clear Creek Bio, Inc. |
| NCT04575038 | Phase 2 | Nov 19, 2020 | Clear Creek Bio, Inc. |
| NCT04425252 | Phase 1/Phase 2 (Phase 2) | Jun 12, 2020 | Clear Creek Bio, Inc. |
| NCT03760666 | Phase 1/Phase 2 (Phase 2) | Nov 26, 2018 | Clear Creek Bio, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Clear Creek Bio, Inc. | For profit | 4 | 4 | 1 | 2018 |
1 organizations
Page 1 / 1